Please select the eligibility criteria that correspond to the clinical trial below.
Title: Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass - a Randomized Control Clinical Trial
Brief Summary: The great saphenous vein is the most commonly used material in coronary vascular bridging operation. Coronary bypass operation to obtain the great saphenous vein is mainly through the incision open groin to ankle. This operation may damage the lymphatic, cause lymph circumfluence obstacle, cause fat liquefaction, scar formation, wound dehiscence, around hematoma and other a series of symptoms.Based on some studies and our experience that vacuum assisted closure （VAC）is effective in complex wound failures following Stripping saphenous vein, we use VAC to prevent seroma formation after Stripping saphenous vein in Coronary bypass. This study is aimed to evaluate the efficacy and economics benefits of early VAC application on postoperative complications and wound healing after Stripping saphenous vein in Coronary bypass in comparison to conventional suction drain.


Options:
A: Inclusion Criteria:

* 30 total patients undergoing panniculectomy alone following massive weight loss
* 30 total patients undergoing formal abdominoplasty (including undermining of skin flaps, rectus fascia plication and liposuction) following massive weight loss
* 30 total non-massive weight loss patients undergoing formal lipo-abdominoplasty
* 30 total patients undergoing ventral hernia repair using acellular dermal matrix
* 30 total patients undergoing bilateral breast reconstruction using acellular dermal matrix with 30 breasts randomized to conventional closed suction (one breast left vs right) and 30 breasts randomized to continuous negative pressure devices (=60 breasts total)

Exclusion Criteria:

* presence of necrotic tissue
* untreated osteomyelitis
* malignancy (except terminal patients for quality of life issues)
* untreated malnutrition
* use on exposed arteries, veins, or organs
* use on non-enteric and unexplored fistulas Special precaution will be taken when using the NPWT device in patients on anticoagulants, exhibiting otherwise difficult hemostasis, or non-adherent patients.
B: Key inclusion criteria BMI greater than or equal to 30 kg/m2 at less than or equal to 22 weeks of gestation Subject is laboring Subject is having an unplanned cesarean section Subject will have Pfannenstiel Skin Incision Subject has the ability to take a picture and email it to a secure account Subject receives prenatal care in the University of Pennsylvania health system and plans to follow up postpartum in the system Subject is greater than or equal to 18 years of age

Key exclusion criteria Subject cannot read or speak English Subject is not 18 years of age Subject does not have ability to send a picture by email Subject has preexisting diabetes mellitus (Type 1 or Type 2) , is using chronic steroids or immune-suppressants, OR being actively treated for a malignancy Subject is undergoing a scheduled cesarean section Subject is allergic to silver
C: Inclusion Criteria:

* Written informed consent
* Coronary heart disease patients to transplant more than 2 vascular bridge
* The thigh groin following from the saphenous vein

Exclusion Criteria:

* Subjects does not agree to participate in clinical trials
* Subjects had a injury, operation history of Thigh
* Subjects having ever received chemotherapy before the surgery
* Subjects with known hypersensitivity to components of the surgical sticky membrane
D: Inclusion Criteria:

* Patients presenting for elective or semi-elective isolated first-time CABG surgery with harvesting of the greater saphenous vein.
* Must be 18 years or older.
* Must live with one hour driving distance from Calgary.
* Must provide written consent.

Exclusion Criteria:

* Previous CABG surgery or previous lower leg surgical intervention.
* In emergent need for surgery.
* Have severe peripheral vascular disease.
* Do not speak and read the English language.
* Have dialysis-dependent renal failure.
* Require chronic steroids.
* Unable to return to clinic for follow-up due to functional or cognitive impairment.

Answer: C